Trusted Partner for Exosome-based Biomarker Development
Numerous pharmaceutical and biotech companies have partnered with Bio-Techne to further their capabilities through the power of exosome isolation, genomic, and proteomic profiling. We have extensive intellectual property related to exosomes and pair it with multiple downstream analysis options and sample inputs to take a single partner from discovery to kitted products.
Bio-Techne can:
- Get versatility in target analytes to accurately characterize and stratify patient populations
- Analyze biofluids that can provide minimally and non-invasive options to obtain critical information
- Create customized experimental approaches based on over a decade of exosome experience
- Utilize regulatory experience to ensure that the approval of your targeted therapy is paired with a cleared assay ready for clinical use
Why Exosomes?
-
Exosomes are secreted by all living cells into all biofluids and provide a snapshot of biological processes
-
Allows for testing with a stable sample, amenable to frozen storage from CSF, plasma, or other biofluids
-
Enables multiomic analysis of gene expression biomarkers (e.g. RNA-seq, splice variants, fusions), DNA (e.g. methylation, mutations), and proteins
-
Exosome collection is non-invasive, so you can use biofluids for dynamic readouts rather than tissue-only biopsies
-
Ability to analyze RNA genomic material protected from degradation by exosomes, for enhanced sensitivity
-
Exosomes are more abundant than cfDNA or CTCs
Tap into our expertise to accelerate your drug development and approval process.
A Kit Targeting Detection of ESR1 Mutations From Circulating Exosomal RNA and Cell-Free DNA
Presented at AACR 2024 by Asuragen, a Bio-Techne Brand
Resource Library
- Case Study: ESR1 Mutation Monitoring
- Genomic Profiling, Advantages of Liquid Biopsy-Based Biomarkers
- Auto-Immune Disease, Advantages of Exosome Diagnostics with Saliva Testing
- Dynamic Neuronal Exosomal Biomarkers in Cell Culture Medium
- Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection
- Video: World CDx Panel: Driving Patient Enrollment & Stratification Through a CDx Partnership
- Webinar: Unlocking the Power of Exosomes: Revolutionizing Cancer Mutation Detection
- Coming Soon: QuantideX® qPCR ESR1 exoMutation Kit
Frequently Asked Questions:
Exosome extraction and analysis will produce higher quality RNA than direct extraction.
Each assay is uniquely quality controlled, as an example of RNA quality control we show here an Ambion® ERCC spiked RNA control assay where each sample is spiked with a known quantity and sequenced. You can see from this assay an approximate dynamic range of the RNA assay.
A significant portion of the transcripts are covered ≥80% of which a large fraction is ≥1kb in length
Observed is blue and not observed is in gray, there is adequate coverage of both total RNA and mRNA.
Diversity/detection in liquid biopsy is the same as tissue. Observed is blue and not observed is in gray. Comparable diversity and detection was determined.
A large percentage of the observed transcripts are shared across one or more biofluids but each biofluid has exclusive components and their own individual signatures.
Exosomes exhibit extended stability at room temperature and are resistant to multiple freeze/thaw cycles with -80°C storage > 10 years.
We work quickly and efficiently to deliver you high quality results. Timing is project dependent.
